Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

The pharmaceutical industry invests $20 billion annually in producing content, yet over three-quarters of it is never or rarely used by field teams. This highlights a massive disconnect between content creation and its relevance to customer engagement.

The pharmaceutical industry is often misunderstood because it communicates through faceless corporate entities. It could learn from tech's "go direct" strategy, where leaders tell compelling stories. Highlighting the scientists and patient journeys behind breakthroughs could dramatically improve public perception and appreciation.

The industry's historical success with large sales forces repeating messages to doctors created a deep-seated cultural mindset. This legacy of "pushing" information is a primary barrier to adopting a more human-centric, digitally native approach based on listening and responding to customer needs.

Pharmaceutical companies often mistakenly believe they lack content. The real issue is the underutilization of existing assets. By redefining, reformatting, or simply changing the visual style of old content, teams can deliver fresh experiences without starting from scratch, a key strategy for established brands.

The vast majority of marketing content created for field sales reps goes unused. Faced with information overload, reps stick with older, familiar materials they know well, ignoring new content. This signals a critical breakdown in content strategy and sales training.

Pharmaceutical companies invest in creating high-quality, patient-centric educational documents. However, these resources often fail to reach patients because physicians are hesitant to distribute materials bearing a corporate logo, creating a "last-mile" delivery problem for crucial information.

Pharmaceutical companies have long used Closed Loop Marketing (CLM) to gather physician feedback during sales calls. However, this data often becomes a wasted opportunity. The critical failure occurs when marketing teams receive these insights but do not act upon them to refine content and strategy, rendering the data collection pointless.

The pharmaceutical industry risks repeating Kodak's failure of inventing but ignoring a disruptive technology. For Kodak, it was digital photography; for pharma, it's AI. The industry possesses vast amounts of data (the new 'film'), but the real danger lies in failing to embrace the AI-driven intelligence layer that can interpret and act on it.